|
7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV13–16 November 2005, Dublin, Ireland |
Uridine supplementation increases subcutaneous fat in patients with HAART-associated lipodystrophy: a randomized, placebo-controlled trial
J Sutinen1, UA Walker2, K Sevastianova1, AM Hakkinen1, M Ristola1 and H Yki-Jarvinen1
1Helsinki University Central Hospital, Helsinki, Finland; 2Freiburg University Hospital, Freiburg, Germany
Antiviral Therapy 2005; Supplement 3:L7 (abstract no. 7)
OBJECTIVES: In vitro, uridine abrogates NRTI-induced mitochondrial toxicity on adipocytes. The aim of the study was to investigate the effects of uridine on highly active antiretroviral therapy (HAART)-associated lipodystrophy (HAL).
METHODS: Twenty patients with HAL were randomized to receive either NucleomaxX®, a dietary supplement which increases uridine serum levels (36 g NucleomaxX® three times a day for 10 days/month) or placebo for 3 months. Body composition was measured using DEXA and MRI. Liver fat was quantified by proton spectroscopy.
RESULTS: Eighteen patients completed the study. There were no significant differences between the groups at baseline.
|
|
||||
| Table 1. | ||||
| NucleomaxX® (n=9) | Placebo (n=9) | |||
| Baseline | 3 months | Baseline | 3 months | |
|
|
||||
| Age (years) | 47 ±2 | – | 47 ±5 | – |
| Body mass index (kg/m2) | 24.7 ±1.2 | 25.1 ±1.3* | 22.2 ±1.0 | 22.4 ±0.9 |
| Total limb fat (g) | 3370 ±890 | 4260 ±940*# | 3110 ±900 | 3340 ±880 |
| Total limb fat (%) | 22.6 ±6.2 | 28.1 ±6.0* | 24.1 ±6.7 | 25.7 ±6.4 |
| Leg fat (g) | 2070 ±530 | 2600 ±490* | 2030 ±660 | 2140 ±570 |
| Arm fat (g) | 1310 ±440 | 1660 ±520* | 1080 ±280 | 1200 ±330 |
| Truncal fat (kg) | 10.6 ±1.8 | 11.6 ±1.9* | 8.5 ±1.5 | 8.5 ±1.4 |
| Proportion of limb fat to total fat (%) | 19.1 ±3.6 | 24.6 ±2.2* | 22.8 ±4.4 | 24.9 ±3.0 |
| Intra-abdominal fat (cm3) | 2320 ±320 | 2520 ±370*# | 2030 ±500 | 1940 ±460 |
| Liver fat (%) | 6.4 ±3.1 | 7.7 ±3.9 | 12.8 ±5.2 | 8.7 ±3.1 |
|
|
||||
| *P<0.05 for change between baseline and 3 months within each study group; #P<0.05 for change between NucleomaxX® and placebo groups; Data are mean ±SEM. | ||||
|
|
||||
CONCLUSIONS: NucleomaxX® increased predominantly the amount of subcutaneous fat, but did not change liver fat content in lipoatrophic patients with unchanged HAART.
Download PDF of this abstract.
2005-11-13
7
Copyright © 2005 - International Medical Press Ltd. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Medical Editor, International Medical Press, 36 St Mary-at-Hill, London EC3R 8DU, United Kingdom.